Johnson & Johnson (JNJ) EV/EBIT Ratio: 22.54x
Is Johnson & Johnson’s EV/EBIT ratio high or low?
Johnson & Johnson's EV/EBIT ratio of 22.54x is 16% above its 5-year average of 19.49x, near the high end of its 5-year range (15.32x–25.38x).
As of Thursday, June 11, 2026. 4.58% above its 12-month average of 21.55x.
JNJ EV/EBIT Ratio Chart
JNJ Average EV/EBIT Ratio Chart
JNJ Current vs Average EV/EBIT Ratio Chart
JNJ EV/EBIT Ratio Metrics
EV/EBIT RATIO
22.54x
EV/EBIT RATIO AVG TTM
21.55x
EV/EBIT RATIO AVG 3Y
19.02x
EV/EBIT RATIO AVG 5Y
19.49x
EV/EBIT RATIO AVG 10Y
19.22x
EV/EBIT RATIO AVG 15Y
17.32x
EV/EBIT RATIO AVG 20Y
15.88x
CURRENT VS TTM AVG
+4.58%
CURRENT VS 3Y AVG
+18.51%
CURRENT VS 5Y AVG
+15.63%
CURRENT VS 10Y AVG
+17.25%
CURRENT VS 15Y AVG
+30.15%
CURRENT VS 20Y AVG
+41.94%
JNJ Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | $577.73B | 22.54x | 21.55x | 19.02x | 19.49x |
| Pfizer Inc. (PFE) | $149.61B | 14.37x | 12.24x | 29.84x | 23.37x |
| Merck & Co., Inc. (MRK) | $298.23B | 18.91x | 12.24x | 31.15x | 27.84x |
| AbbVie Inc. (ABBV) | $399.86B | 26.80x | 39.30x | 31.81x | 26.56x |
| Eli Lilly and Company (LLY) | $1.10T | 32.58x | 33.00x | 49.79x | 44.38x |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 12.14x | 11.35x | 15.41x | 18.89x |
Johnson & Johnson EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for Johnson & Johnson (JNJ)?
- The EV/EBIT ratio for JNJ stock is 22.54x.
- Is Johnson & Johnson's EV/EBIT ratio high or low?
- Johnson & Johnson's EV/EBIT ratio of 22.54x is 16% above its 5-year average of 19.49x, near the high end of its 5-year range (15.32x–25.38x).
- What is the TTM average EV/EBIT ratio for Johnson & Johnson (JNJ)?
- The TTM average EV/EBIT ratio for JNJ stock is 21.55x.
- What is the 3Y average EV/EBIT ratio for Johnson & Johnson (JNJ)?
- The 3Y average EV/EBIT ratio for JNJ stock is 19.02x.
- What is the 5Y average EV/EBIT ratio for Johnson & Johnson (JNJ)?
- The 5Y average EV/EBIT ratio for JNJ stock is 19.49x.
- What is the 10Y average EV/EBIT ratio for Johnson & Johnson (JNJ)?
- The 10Y average EV/EBIT ratio for JNJ stock is 19.22x.
- What is the 15Y average EV/EBIT ratio for Johnson & Johnson (JNJ)?
- The 15Y average EV/EBIT ratio for JNJ stock is 17.32x.
- What is the 20Y average EV/EBIT ratio for Johnson & Johnson (JNJ)?
- The 20Y average EV/EBIT ratio for JNJ stock is 15.88x.
Johnson & Johnson EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-11 | 22.54x |
| 2026-06-10 | 22.36x |
| 2026-06-09 | 22.22x |
| 2026-06-08 | 21.76x |
| 2026-06-05 | 21.82x |
| 2026-06-04 | 21.38x |
| 2026-06-03 | 20.92x |
| 2026-06-02 | 20.89x |
| 2026-06-01 | 20.94x |
| 2026-05-29 | 21.12x |
| 2026-05-28 | 21.63x |
| 2026-05-27 | 21.68x |
| 2026-05-26 | 21.57x |
| 2026-05-22 | 21.97x |
| 2026-05-21 | 21.72x |
| 2026-05-20 | 21.49x |
| 2026-05-19 | 21.56x |
| 2026-05-18 | 21.46x |
| 2026-05-15 | 21.25x |
| 2026-05-14 | 21.63x |
| 2026-05-13 | 21.60x |
| 2026-05-12 | 21.02x |
| 2026-05-11 | 20.75x |
| 2026-05-08 | 20.74x |
| 2026-05-07 | 20.85x |
| 2026-05-06 | 21.05x |
| 2026-05-05 | 21.14x |
| 2026-05-04 | 21.01x |
| 2026-05-01 | 21.29x |
| 2026-04-30 | 21.54x |
| 2026-04-29 | 21.31x |
| 2026-04-28 | 21.35x |
| 2026-04-27 | 21.12x |
| 2026-04-24 | 21.32x |
| 2026-04-23 | 21.62x |
| 2026-04-22 | 21.19x |
| 2026-04-21 | 22.48x |
| 2026-04-20 | 22.91x |
| 2026-04-17 | 23.24x |
| 2026-04-16 | 23.27x |
| 2026-04-15 | 23.66x |
| 2026-04-14 | 23.80x |
| 2026-04-13 | 23.59x |
| 2026-04-10 | 23.64x |
| 2026-04-09 | 23.91x |
| 2026-04-08 | 23.91x |
| 2026-04-07 | 23.64x |
| 2026-04-06 | 23.88x |
| 2026-04-02 | 24.07x |
| 2026-04-01 | 24.18x |
| 2026-03-31 | 24.21x |
| 2026-03-30 | 24.02x |
| 2026-03-27 | 23.83x |
| 2026-03-26 | 23.72x |
| 2026-03-25 | 23.78x |
| 2026-03-24 | 23.34x |
| 2026-03-23 | 23.35x |
| 2026-03-20 | 23.35x |
| 2026-03-19 | 23.56x |
| 2026-03-18 | 23.53x |
| 2026-03-17 | 23.61x |
| 2026-03-16 | 24.09x |
| 2026-03-13 | 23.93x |
| 2026-03-12 | 23.98x |
| 2026-03-11 | 24.07x |
| 2026-03-10 | 24.14x |
| 2026-03-09 | 24.03x |
| 2026-03-06 | 23.82x |
| 2026-03-05 | 23.75x |
| 2026-03-04 | 24.29x |
| 2026-03-03 | 24.42x |
| 2026-03-02 | 24.60x |
| 2026-02-27 | 24.58x |
| 2026-02-26 | 24.11x |
| 2026-02-25 | 24.27x |
| 2026-02-24 | 24.38x |
| 2026-02-23 | 24.34x |
| 2026-02-20 | 24.02x |
| 2026-02-19 | 24.44x |
| 2026-02-18 | 24.26x |
| 2026-02-17 | 24.10x |
| 2026-02-13 | 24.11x |
| 2026-02-12 | 24.22x |
| 2026-02-11 | 23.87x |
| 2026-02-10 | 25.22x |
| 2026-02-09 | 25.25x |
| 2026-02-06 | 25.38x |
| 2026-02-05 | 25.16x |
| 2026-02-04 | 24.83x |
| 2026-02-03 | 24.69x |
| 2026-02-02 | 24.45x |
| 2026-01-30 | 24.10x |
| 2026-01-29 | 24.10x |
| 2026-01-28 | 24.15x |
| 2026-01-27 | 23.81x |
| 2026-01-26 | 23.52x |
| 2026-01-23 | 23.38x |
| 2026-01-22 | 23.21x |
| 2026-01-21 | 23.16x |
| 2026-01-20 | 23.19x |
| 2026-01-16 | 23.23x |
| 2026-01-15 | 23.32x |
| 2026-01-14 | 23.22x |
| 2026-01-13 | 22.72x |
| 2026-01-12 | 22.33x |
| 2026-01-09 | 21.79x |
| 2026-01-08 | 21.93x |
| 2026-01-07 | 22.10x |
| 2026-01-06 | 21.83x |
| 2026-01-05 | 21.78x |
| 2026-01-02 | 22.09x |
| 2025-12-31 | 22.05x |
| 2025-12-30 | 22.04x |
| 2025-12-29 | 22.11x |
| 2025-12-26 | 22.12x |
| 2025-12-24 | 22.13x |
| 2025-12-23 | 21.93x |
| 2025-12-22 | 22.09x |
| 2025-12-19 | 21.99x |
| 2025-12-18 | 22.19x |
| 2025-12-17 | 22.39x |
| 2025-12-16 | 22.29x |
| 2025-12-15 | 22.78x |
| 2025-12-12 | 22.52x |
| 2025-12-11 | 22.36x |
| 2025-12-10 | 22.01x |
| 2025-12-09 | 21.34x |
| 2025-12-08 | 21.51x |
| 2025-12-05 | 21.54x |
| 2025-12-04 | 21.60x |
| 2025-12-03 | 21.88x |
| 2025-12-02 | 21.89x |
| 2025-12-01 | 21.89x |
| 2025-11-28 | 22.04x |
| 2025-11-26 | 22.11x |
| 2025-11-25 | 22.02x |
| 2025-11-24 | 21.96x |
| 2025-11-21 | 21.74x |
| 2025-11-20 | 21.66x |
| 2025-11-19 | 21.60x |
| 2025-11-18 | 21.35x |
| 2025-11-17 | 21.30x |
| 2025-11-14 | 20.93x |
| 2025-11-13 | 20.87x |
| 2025-11-12 | 20.78x |
| 2025-11-11 | 20.72x |
| 2025-11-10 | 20.18x |
| 2025-11-07 | 19.99x |
| 2025-11-06 | 20.03x |
| 2025-11-05 | 19.93x |
| 2025-11-04 | 20.02x |
| 2025-11-03 | 19.96x |
| 2025-10-31 | 20.22x |
| 2025-10-30 | 20.24x |
| 2025-10-29 | 19.99x |
| 2025-10-28 | 20.03x |
| 2025-10-27 | 20.37x |
| 2025-10-24 | 20.38x |
| 2025-10-23 | 20.59x |
| 2025-10-22 | 20.63x |
| 2025-10-21 | 22.33x |
| 2025-10-20 | 22.53x |
| 2025-10-17 | 22.48x |
| 2025-10-16 | 22.36x |
| 2025-10-15 | 22.25x |
| 2025-10-14 | 22.22x |
| 2025-10-13 | 22.22x |
| 2025-10-10 | 22.20x |
| 2025-10-09 | 22.24x |
| 2025-10-08 | 22.09x |
| 2025-10-07 | 22.01x |
| 2025-10-06 | 21.93x |
| 2025-10-03 | 21.98x |
| 2025-10-02 | 21.69x |
| 2025-10-01 | 21.70x |
| 2025-09-30 | 21.63x |
| 2025-09-29 | 21.21x |
| 2025-09-26 | 21.01x |
| 2025-09-25 | 20.79x |
| 2025-09-24 | 20.68x |
| 2025-09-23 | 20.67x |
| 2025-09-22 | 20.41x |
| 2025-09-19 | 20.62x |
| 2025-09-18 | 20.40x |
| 2025-09-17 | 20.73x |
| 2025-09-16 | 20.65x |
| 2025-09-15 | 20.75x |
| 2025-09-12 | 20.83x |
| 2025-09-11 | 20.87x |
| 2025-09-10 | 20.58x |
| 2025-09-09 | 20.71x |
| 2025-09-08 | 20.83x |
| 2025-09-05 | 20.87x |
| 2025-09-04 | 20.90x |
| 2025-09-03 | 20.82x |
| 2025-09-02 | 20.83x |
| 2025-08-29 | 20.73x |
| 2025-08-28 | 20.54x |
| 2025-08-27 | 20.69x |
| 2025-08-26 | 20.66x |
| 2025-08-25 | 20.86x |
| 2025-08-22 | 20.96x |
| 2025-08-21 | 20.92x |
| 2025-08-20 | 20.91x |
| 2025-08-19 | 20.80x |
| 2025-08-18 | 20.63x |
| 2025-08-15 | 20.67x |
| 2025-08-14 | 20.46x |
| 2025-08-13 | 20.43x |
| 2025-08-12 | 20.25x |
| 2025-08-11 | 20.36x |
| 2025-08-08 | 20.31x |
| 2025-08-07 | 20.12x |
| 2025-08-06 | 20.01x |
| 2025-08-05 | 20.03x |
| 2025-08-04 | 20.06x |
| 2025-08-01 | 19.66x |
| 2025-07-31 | 19.38x |
| 2025-07-30 | 19.65x |
| 2025-07-29 | 19.74x |
| 2025-07-28 | 19.54x |
| 2025-07-25 | 19.76x |
| 2025-07-24 | 19.90x |
| 2025-07-23 | 19.19x |
| 2025-07-22 | 19.06x |
| 2025-07-21 | 18.67x |
| 2025-07-18 | 18.60x |
| 2025-07-17 | 18.52x |
| 2025-07-16 | 18.72x |
| 2025-07-15 | 17.66x |
| 2025-07-14 | 17.84x |
| 2025-07-11 | 17.85x |
| 2025-07-10 | 17.94x |
| 2025-07-09 | 17.78x |
| 2025-07-08 | 17.73x |
| 2025-07-07 | 17.67x |
| 2025-07-03 | 17.75x |
| 2025-07-02 | 17.70x |
| 2025-07-01 | 17.74x |
| 2025-06-30 | 17.40x |
| 2025-06-27 | 17.36x |
| 2025-06-26 | 17.31x |
| 2025-06-25 | 17.34x |
| 2025-06-24 | 17.33x |
| 2025-06-23 | 17.24x |
| 2025-06-20 | 17.07x |
| 2025-06-18 | 17.17x |
| 2025-06-17 | 17.36x |
| 2025-06-16 | 17.67x |
| 2025-06-13 | 17.87x |
| 2025-06-12 | 17.83x |
| 2025-06-11 | 17.67x |
| 2025-06-10 | 17.80x |
| 2025-06-09 | 17.67x |
| 2025-06-06 | 17.65x |
| 2025-06-05 | 17.50x |
| 2025-06-04 | 17.45x |
| 2025-06-03 | 17.58x |
| 2025-06-02 | 17.69x |
| 2025-05-30 | 17.67x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato